Liu Qifa
- 3 Bom • 1 avaliações
- 33 anos de experiência
- China, Pequim, Lu Daopei Hematology Hospital
Dr. Hila Magen, MD, leads the Multiple Myeloma and Amyloidosis Unit at Sheba Medical Center. She is a hemato-oncologist with over 35 years of experience. She is a leading Israeli expert in multiple myeloma and plasma cell disorders.
She runs a program that provides personalized care and early access to clinical trials. This includes CAR-T therapy for high-risk and relapsed or refractory myeloma and amyloidosis. Dr. Magen is a principal investigator in point-of-care CAR-T studies. She brings new immunotherapies into routine care.
Training: Fellowships in Multiple Myeloma (UAMS) and Lymphocytic Leukemia (MD Anderson). Academic: Instructor, Tel Aviv University. Research: Author of 100+ publications, contributor to landmark myeloma studies, and reviewer for international journals.
Dr. Iris Kventsel, MD, is a pediatric hemato-oncologist and bone marrow transplant (BMT) specialist at Sheba Medical Center. She is an attending physician in the Pediatric Hemato-Oncology and BMT Division at the Edmond and Lily Safra Children’s Hospital. Her clinical focus is pediatric sarcomas, including Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma.
She provides multidisciplinary care, including transplant and cellular therapies. She also uses current chemotherapy protocols and targeted therapies for complex childhood cancers.
Her research focuses on genetic cancer predisposition, including Li-Fraumeni syndrome, and cancer susceptibility genes. She has published in pediatric oncology, stem cell biology, and surgical oncology (HIPEC). She is on the academic staff at Tel Aviv University. Education: MD, Technion; Pediatrics residency, Assaf HaRofeh; Pediatric Hemato-Oncology fellowship, Sheba.
Dr. Abraham Avigdor, MD, is Director of the Institute of Hematology and Co‑Director of the Hematology & Bone Marrow Transplantation Division at Sheba Medical Center. He is an international leader in lymphoma, CAR‑T, and advanced hemato‑oncology with more than 35 years of experience. His clinical focus includes lymphomas, multiple myeloma, and complex blood cancers.
He is a pioneer in CAR‑T integration. He leads cellular therapy and bone marrow transplantation programs (autologous and allogeneic). He also advances stem cell therapies and precision diagnostics, including PET/CT‑based prognostics. His work includes immunotherapy and targeted regimens and the development of innovative, data‑driven protocols.
He collaborates with LYSA, EMCL, and international PET groups. He has authored more than 130 publications. Key roles include Founder and President of the Israeli Lymphoma Working Group, former Chair of the Israeli Lymphoma Study Group, and Senior Lecturer at Tel Aviv University. Education: MD, Ben‑Gurion University; residency, Sheba Medical Center; postdoctoral fellowship, Weizmann Institute. Awards include the Knesset Prize, the Israeli Ministry of Health Award, and the Sackler Prize.
Prof. Elad Jacoby, MD, heads the Pediatric Cell Therapy Center at Sheba Medical Center. He is the Medical Director of the Advanced Biotherapy Center. He is a pioneer of pediatric CAR T‑cell therapy in Israel. He led one of the first national leukemia programs. He has almost 20 years of clinical and research experience.
He specializes in CAR T‑cell therapy, bone marrow and stem cell transplantation, and high‑risk pediatric leukemias and lymphomas. He leads international clinical trials and has authored over 240 publications. His collaborations include Johns Hopkins Hospital and the U.S. National Cancer Institute. He is an Associate Professor at Tel Aviv University. He received his MD from Tel Aviv University, completed residency at Sheba Medical Center, and fellowships at Johns Hopkins and the National Cancer Institute. He is board‑certified in Pediatrics and in Pediatric Hematology and Oncology. He serves on the IBFM CAR T‑Cell Taskforce and the Sheba Institutional Review Board. He leads the integration of CAR T‑cell therapy with transplantation.
O Prof. Omay possui mais de 65 artigos científicos em hematologia e é especialista em transplantes de células-tronco, tendo sido treinado em instituições de prestígio, incluindo a Universidade Hacettepe e a Universidade Ege.
O Prof. Baytan é especializado em cânceres infantis e tratamentos de leucemia, com mais de 15 artigos publicados em periódicos internacionais.
O Dr. Omer Dogru é especialista em hematologia e oncologia pediátrica, com vasta experiência em transplante de células-tronco haploidênticas no Hospital Universitário Biruni.
Professor Associado em Hematologia com mais de 50 publicações – Dr. Eren é especialista em transplante de células-tronco haploidênticas no Hospital Universitário Biruni.
Com mais de 40 anos em hematologia-oncologia pediátrica, o Dr. Apak é especialista em tratamentos avançados como transplante de medula óssea e terapia com células T CAR.
O Dr. Prakash Pandit é especialista em técnicas avançadas de radioncologia no HCG Manavata Cancer Centre.
É especialista em transplante de células-tronco haploidêntico no Liv Hospital Vadistanbul – um centro líder para procedimentos hematológicos complexos.
O Professor Associado Ali Hakan Kaya é especialista em transplante haploidentitário de células estaminais no Hospital Universitário Biruni, com mais de uma década de experiência em hematologia.
Mais de 30 anos de especialização em hematologia-oncologia pediátrica – Dr. Lopez Ibor lidera a Unidade de Hematologia e Oncologia Pediátrica do Grupo HM.
O Dr. Girish Badarkhe é especialista em transplantes de medula óssea, com mais de 13 anos dedicados a casos complexos de hematologia no HCG Manavata Cancer Centre.